Ginkgo Bioworks (DNA) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Special Meeting scheduled for August 14, 2024, to vote on three key proposals: a reverse stock split, officer exculpation, and charter updates.
The meeting will be held virtually to enhance accessibility and reduce environmental impact.
Shareholders of record as of June 24, 2024, are eligible to vote; Class A shares have one vote each, Class B shares have ten votes each, and Class C shares have no voting rights.
Proxy materials are available online, and voting can be done via internet, phone, or mail.
Voting matters and shareholder proposals
Proposal 1: Approve a reverse stock split (1:20 to 1:40) for Class A and B shares to help regain NYSE compliance and reduce outstanding shares.
Proposal 2: Amend charter to permit officer exculpation, aligning with recent Delaware law changes.
Proposal 3: Update charter to remove outdated provisions related to the Soaring Eagle merger and domestication, and modernize administrative language.
Board recommends voting FOR all three proposals.
Board of directors and corporate governance
Board retains discretion to implement or abandon proposals up to one year after approval.
Board structure allows Class B shareholders to elect one-quarter of directors if they hold at least 2% of common stock.
Board committees include audit, nominating and governance, and compensation; at least one Class B director must serve on most committees.
Latest events from Ginkgo Bioworks
- Cash burn cut by 55% as focus shifts to autonomous labs and AI-driven automation partnerships.DNA
Q4 20253 Mar 2026 - Q2 2024 revenue dropped 30% as restructuring and $47.9M goodwill impairment hit results.DNA
Q2 20241 Feb 2026 - Shifting to a focused, platform-driven model with new tools and data services for biotech innovation.DNA
Morgan Stanley 22nd Annual Global Healthcare Conference21 Jan 2026 - Q3 revenue up 61% to $89M, loss narrows, and 2024 guidance raised to $215–235M.DNA
Q3 202414 Jan 2026 - Direct sales, biopharma partnerships, and automation drive growth and market leadership.DNA
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Cost cuts, new tools, and automation drive efficiency, but 2025 outlook remains cautious.DNA
Q4 202427 Dec 2025 - Flexible $500M shelf registration targets synthetic biology, automation, and biosecurity growth.DNA
Registration Filing16 Dec 2025 - Votes sought on reverse split, officer exculpation, and charter updates to maintain NYSE listing.DNA
Proxy Filing1 Dec 2025 - 2025 proxy covers director elections, auditor ratification, say-on-pay, and governance updates.DNA
Proxy Filing1 Dec 2025